Physician profile
Eric Wiebe
NPI 1477561512
$968.16
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $11.49 · 2022: $145 · 2023: $352 · 2024: $63.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395 · Travel and Lodging: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.42 |
| Travel and Lodging | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $174.16 | 2023 | Minimed 780g |
| Pfizer INC. | $124.65 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $120.94 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Otsuka America Pharmaceutical, INC. | $78.14 | 2022-2024 | Jynarque |
| Portola Pharmaceuticals, LLC | $68.96 | 2019 | |
| Amgen INC. | $68.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $50.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.10 | 2024 | Entyvio |
| Mylan Specialty L.P. | $38.54 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $36.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.88 | 2023 | Eliquis |
| Pulmonx Corporation | $28.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $23.55 | 2022 | |
| Abbvie INC. | $20.59 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wiebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.